We are live on ! Find out more
NVAX icon

Novavax
NVAX

143 hedge funds and large institutions have $623M invested in Novavax in 2014 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 61 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 30

47% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 15

4% more funds holding

Funds holding: 137 → 143 (+6)

1% less capital invested

Capital invested by funds: $632M → $623M (-$9.27M)

68% less call options, than puts

Call options by funds: $3.1M | Put options by funds: $9.59M

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
143
Holders Change
+6
Holders Change %
+4.38%
% of All Funds
4.15%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
22
Increased
61
Reduced
30
Closed
15
Calls
$3.1M
Puts
$9.59M
Net Calls
-$6.49M
Net Calls Change
-$5.47M

Top Buyers

1
BB
BB Biotech
Switzerland
+$33.9M
2
Wells Fargo
Wells Fargo
California
+$11.6M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$7.67M
4
Invesco
Invesco
Georgia
+$6.11M
5
BFA
BlackRock Fund Advisors
California
+$4.31M

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$7.21M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$6.34M
3
AGCJ
Alden Global Capital (Jersey)
Jersey
-$6.03M
4
Franklin Resources
Franklin Resources
California
-$2.65M
5
SM
Sabby Management
Florida
-$1.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$104M +$121K +1,340 +0.1%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$49.7M +$7.67M +84,840 +17%
Invesco
3
Invesco
Georgia
$35.1M +$6.11M +67,588 +19%
BFA
4
BlackRock Fund Advisors
California
$33.5M +$4.31M +47,714 +13%
BB
5
BB Biotech
Switzerland
$31.3M +$33.9M +375,000 New
Wells Fargo
6
Wells Fargo
California
$30.4M +$11.6M +128,557 +54%
Vanguard Group
7
Vanguard Group
Pennsylvania
$29.5M +$1.13M +12,532 +4%
State Street
8
State Street
Massachusetts
$29M +$3.55M +39,279 +13%
BIT
9
BlackRock Institutional Trust
California
$27.7M +$1.45M +16,011 +5%
RCM
10
RA Capital Management
Massachusetts
$21.1M -$7.21M -79,733 -24%
CCM
11
Camber Capital Management
Massachusetts
$19.8M – – –
Wellington Management Group
12
Wellington Management Group
Massachusetts
$16.8M -$783K -8,665 -4%
BNP Paribas Asset Management
13
BNP Paribas Asset Management
France
$16M +$1.21M +13,342 +7%
Franklin Resources
14
Franklin Resources
California
$15.1M -$2.65M -29,360 -14%
Northern Trust
15
Northern Trust
Illinois
$11.4M +$2.34M +25,888 +23%
NC
16
Northpointe Capital
Michigan
$8.62M -$29.8K -330 -0.3%
EAM
17
Eventide Asset Management
Massachusetts
$7.96M – – –
Ameriprise
18
Ameriprise
Minnesota
$6.61M -$922K -10,197 -11%
CS
19
Credit Suisse
Switzerland
$6.27M +$1.1M +12,159 +19%
CAM
20
Cormorant Asset Management
Massachusetts
$6.25M – – –
Bank of New York Mellon
21
Bank of New York Mellon
New York
$5.86M +$900K +9,963 +17%
Morgan Stanley
22
Morgan Stanley
New York
$5.84M +$188K +2,081 +3%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$5.55M -$502K -5,556 -8%
BBA
24
Baker Bros. Advisors
New York
$5.1M – – –
WHI
25
William Harris Investors
Illinois
$4.62M +$544K +6,019 +12%
1
2 3 4 5

NVAX Hedge Fund Activity: Q3 2014 in Review

143 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2014, worth a combined $623M — down 1.5% from $632M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new NVAX positions and 15 closed out — a net gain of 7 holders — while 61 added to existing stakes and 30 trimmed.

The largest buyer was BB Biotech, opening a new position worth an estimated $33.9M. The largest seller was RA Capital Management, cutting an estimated $7.21M.

  • 143 institutional investors held Novavax (NVAX) as of Q3 2014, up from 137 in Q2 2014.
  • Funds reported $623M of Novavax stock for Q3 2014, down 1.5% quarter-over-quarter.
  • 22 funds opened new Novavax positions in Q3 2014 and 15 closed out, a net change of +7 holders.
  • The largest Novavax buyer in Q3 2014 was BB Biotech, an estimated $33.9M added.
  • The largest Novavax seller in Q3 2014 was RA Capital Management, an estimated $7.21M sold.

Based on aggregated 13F filings for Q3 2014.